Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.49 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734503 | 1.00 | TRPV1 (0.49) | TRPV1CHRM3CHRM2CHRM1HTR1A | |
| SCHEMBL2733639 | 1.00 | TRPV1 (0.49) | TRPV1CHRM3CHRM2CHRM1HTR1A | |
| SCHEMBL13091093 | 0.82 | ACHE (0.39) | TRPV1 | |
| SCHEMBL4813078 | 0.79 | CHRM3 (0.65) | CHRM3CHRM2CHRM1HTR1AHTR7 | |
| SCHEMBL597327 | 0.79 | CYP2A6 (0.41) | TRPV1CHRM3CHRM2CHRM1TSHR | |
| SCHEMBL14591308 | 0.79 | CHRM3 (0.69) | CHRM3CHRM2CHRM1HTR1AHTR7 | |
| SCHEMBL472446 | 0.79 | CHRM2 (0.67) | CHRM3CHRM2CHRM1CYP1A2DRD2 | |
| SCHEMBL23045125 | 0.78 | CHRM3 (0.42) | TRPV1CHRM3 | |
| SCHEMBL23045122 | 0.78 | TRPV1 (0.45) | TRPV1CHRM3HTR1AHTR7CYP2D6 | |
| SCHEMBL23045121 | 0.78 | TRPV1 (0.45) | TRPV1CHRM3HTR1AHTR7CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088826-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl-groups; vanilloid receptor antagonists; analgesics antiinflammatory agent; urogenital disorders | XENTION LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | TAJIMI MASAOMI | 2009-08-20 | — | — | US | disclosed |
| US-7544716-B2 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists | XENTION LIMITED (GB) | 2009-06-09 | — | — | US | disclosed |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | XENTION LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-7423175-B2 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2008-09-09 | — | — | US | disclosed |
| US-7381840-B2 | 2-Hydroxy-1,2,3,4-tetrahydronaphthalenes substituted in the 8-position with a biphenylcarbonylamino-, biphenylcarbonylaminoalkyl-, biphenylaminocarbonylamino-, or biphenylaminocarbonylaminoalkyl- group; vanilloid receptor antagonists | XENTION LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | BAYER HEALTHCARE AG (DE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027187-A1 | Hydroxy-tetrahydro-naphthalenylurea derivatives | HVCN1, NMUR1, OPRL1 | TRPV1 31/4885CHRM3 551/4885CHRM2 358/4885 |
| US-20090209514-A1 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | OPRL1, TRPV1, LTB4R | TRPV1 2/4885CHRM3 370/4885CHRM2 274/4885 |
| US-20080275047-A1 | TETRAHYDRO-NAPHTHALENE DERIVATIVES | TNNC1, CACNA1H, TNNI3 | TRPV1 13/4885CHRM3 412/4885CHRM2 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.